Treatments no longer in development for rheumatoid arthritis.
Keystone
E
E
The Centre for Advanced Therapeutics, Mount Sinai Hospital and University of Toronto, Canada. edkeystone@mtsinai.on.ca
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D016176:T-Lymphocyte Subsets / Q000276:immunology; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D016207:Cytokines; D061965:Matrix Metalloproteinase Inhibitors; D014409:Tumor Necrosis Factor-alpha